ALK a novel lymphoma-associated tumor antigen for vaccination strategies (Q35614635)

9 August 2017

1 reference

title

ALK a novel lymphoma-associated tumor antigen for vaccination strategies (English)

1 reference

Carlo Gambacorti-Passerini

9 August 2017

author

series ordinal

2

object named as

Carlo Gambacorti-Passerini

0 references

Lorena Passoni

object named as

Lorena Passoni

series ordinal

1

0 references

publication date

1 October 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

44

1 reference

9 August 2017

issue

10

1 reference

9 August 2017

page(s)

1675-1681

1 reference

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Translocations involving anaplastic lymphoma kinase (ALK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Cancer genetics and tumor antigens: time for a combined view?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Tumor-specific shared antigenic peptides recognized by human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Challenges in the development of effective peptide vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Spinning molecular immunology into successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Cancer vaccines: progress reveals new complexities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Dendritic cell based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Generation of dendritic cell-based vaccines for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

21 January 2018

Designing HER2 vaccines

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Lymphocytic infiltration and survival in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Anti-idiotype vaccines for human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Adjuvant immunotherapy for solid tumors: from promise to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Expression of the ALK tyrosine kinase gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Time dependency of the influence of prognostic factors on relapse in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Immunochemical studies of antigenic lymphoma-associated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000099625

10.1080/1042819031000099625

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference